LX6171 High Dose + LX6171 Low Dose + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Age-Related Memory Disorders
Conditions
Age-Related Memory Disorders
Trial Timeline
Feb 1, 2008 → —
NCT ID
NCT00691808About LX6171 High Dose + LX6171 Low Dose + Placebo
LX6171 High Dose + LX6171 Low Dose + Placebo is a phase 2 stage product being developed by Lexicon Pharmaceuticals for Age-Related Memory Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00691808. Target conditions include Age-Related Memory Disorders.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00691808 | Phase 2 | Completed |
Competing Products
20 competing products in Age-Related Memory Disorders